Key result
Continuous subcutaneous insulin infusion in T1DM adolescents was associated with lower carotid intima-media thickness compared to multiple daily injections (0.56 vs 0.61 mm, p=0.04).
Why the study?
The benefits of continuous subcutaneous insulin infusion compared to multiple daily injections on long-term metabolic control and outcomes in type 1 diabetes mellitus remain debated.
Does continuous subcutaneous insulin infusion improve vascular function and myocardial performance compared to multiple daily injections in adolescents with Type 1 Diabetes Mellitus?
Observational (n=180)
Does continuous subcutaneous insulin infusion improve vascular function and myocardial performance compared to multiple daily injections in adolescents with Type 1 Diabetes Mellitus?
Absolute Event Rate: 0.56% vs 0.61%
p-value: p=0.04
Continuous subcutaneous insulin infusion in adolescents with Type 1 diabetes is associated with better glycemic control, vascular function, and myocardial performance compared to multiple daily injections.
Should not yet change practice in T1DM adolescents; leaves open CSII vascular benefits for randomized confirmation.
Introduction Multiple daily injections (MDI) and continuous subcutaneous insulin infusion (CSII) are two modalities of treating type 1 diabetes mellitus (T1DM). The benefits of CSII on long-term metabolic control and outcomes compared to those of MDI are still debated. We investigated both vascular function and myocardial performance in T1DM adolescents on MDI or CSII treatment. Methods One hundred twenty-three T1DM subjects (mean age 14.16±2.55 years), 63 on MDI regimen, 60 on CSII, and 57 controls were enrolled. Anthropometric and biochemical characteristics were evaluated. Ultrasound assessments of carotid intima-media thickness (cIMT), flow-mediated dilatation of brachial artery, anteroposterior diameter of the infrarenal abdominal aorta (APAO), and transthoracic echocardiography were performed. Results T1DM subjects on the CSII regimen showed better glycemic control than those on MDI, expressed as glycated haemoglobin (HbA1c). c-IMT and APAO were higher in MDI than CSII patients (0.61±0.11 mm vs. 0.56±0.07 mm, p=0.04; 13.61±3.29 mm vs. 11.65±1.84 mm, p=0.01, respectively). Left and right Tei index and left E/e’ ratio were higher in MDI than CSII subjects (0.82±0.40 vs. 0.52±0.19, p=0.002; 0.86±0.41 vs. 0.64±0.1, p=0.02; 5.89±2.0 vs. 4.73±1.59, p=0.02, respectively). Multiple regression analyses showed that glucose level, HbA1c and diabetes onset were significantly related to vascular and echocardiographic parameters in MDI and CSII patients. Conclusions CSII regimen in T1DM adolescents improves glycemic control and seems to ameliorate endothelial function and global myocardial performance as compared to MDI therapy.
No takes yet. Share an insight, caveat, or question.
Damato et al. (2021) conducted an observational in Type 1 Diabetes Mellitus (n=180). Continuous subcutaneous insulin infusion (CSII) vs. Multiple daily injections (MDI) was evaluated on Carotid intima-media thickness (cIMT) (p=0.04). Continuous subcutaneous insulin infusion in T1DM adolescents was associated with lower carotid intima-media thickness compared to multiple daily injections (0.56 vs 0.61 mm, p=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: